+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Platelet Lysate Market Report and Forecast 2023-2031

  • PDF Icon


  • 140 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805801
The global human platelet lysate market value was USD 50.7 billion in 2022, driven by the increasing demand for regenerative medicine across the globe. The market size is anticipated to grow at a CAGR of 3.6% during the forecast period of 2023-2031 to achieve a value of USD 69.6 billion by 2031.

Human Platelet Lysate: Introduction

Human platelet lysate (HPL) is a cell culture supplement derived from human platelets, primarily used in regenerative medicine and cell therapy applications. It contains growth factors, cytokines, and other bioactive components that promote cell proliferation, differentiation, and tissue regeneration. HPL serves as an alternative to traditional animal-derived culture supplements and offers several advantages, including better cell viability, reduced risk of contamination, and improved clinical outcomes.

Key Trends in the Human Platelet Lysate Market

Key trends in the market for human platelet lysate include:

  • Increasing demand for regenerative medicine: The field of regenerative medicine is rapidly growing, driven by the need for innovative therapies to treat various diseases and injuries. Human platelet lysate plays a crucial role in supporting cell-based therapies, including stem cell transplantation, tissue engineering, and wound healing. As the demand for regenerative medicine continues to rise, the market for human platelet lysate is expected to witness significant growth
  • Focus on quality and safety: With the growing importance of cell-based therapies in clinical practice, ensuring the quality and safety of human platelet lysate has become paramount. Manufacturers are implementing stringent quality control measures to ensure the absence of contaminants, such as viruses and endotoxins, in their products. Additionally, regulatory authorities are establishing guidelines and standards for the production and use of human platelet lysate, further emphasizing the importance of quality and safety
  • Advancements in manufacturing processes: The manufacturing processes for human platelet lysate are continuously evolving to improve product consistency, scalability, and cost-effectiveness. Manufacturers are exploring new methods, such as freeze-drying and pathogen inactivation techniques, to enhance the stability and shelf life of the lysate. These advancements enable easier storage, transportation, and use of human platelet lysate, expanding its applicability in both research and clinical settings

Human Platelet Lysate Market Segmentations

Market Breakup by Type

  • Heparin-based Human Platelet Lysate
  • Heparin-free Human Platelet Lysate
  • Others

Market Breakup by Applications

  • Research
  • Therapeutic
  • Others

Market Breakup by End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

Market Breakup by Distribution Channel

  • Online Stores
  • Retail Stores
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Human Platelet Lysate Market Scenario

The market for human platelet lysate (HPL) is experiencing substantial growth as it plays a pivotal role in the field of regenerative medicine and cell-based therapies. HPL, derived from human platelets, contains valuable growth factors and bioactive components that promote cell proliferation and tissue regeneration. It serves as a safer and more effective alternative to animal-derived culture supplements, driving its widespread adoption in research laboratories, biopharmaceutical companies, and clinical settings.

The market is primarily driven by the increasing demand for regenerative medicine, which aims to develop innovative therapies for various diseases and injuries. HPL supports the growth and differentiation of stem cells, making it a vital component in tissue engineering, wound healing, and cell transplantation procedures. As regenerative medicine continues to gain momentum, the demand for high-quality HPL is expected to rise significantly.

Quality and safety are paramount in the market, with manufacturers implementing stringent quality control measures to ensure product purity and minimize the risk of contamination. Regulatory authorities are also establishing guidelines and standards to ensure the safe and effective use of HPL in clinical applications.

Advancements in manufacturing processes, including freeze-drying and pathogen inactivation techniques, are enhancing the stability and shelf life of HPL products. These developments improve product consistency, scalability, and cost-effectiveness, facilitating their broader utilization in research and clinical settings.

Collaborations and partnerships among researchers, clinicians, and biopharmaceutical companies are driving innovation in the field of HPL. These collaborations foster knowledge sharing, research collaborations, and the development of standardized protocols, further propelling market growth.

Human Platelet Lysate Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Merck KGaA
  • Compass Biomedical, Inc
  • STEMCELL Technologies Inc
  • Sartorius AG
  • Life Science Group Ltd.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetic Gastroparesis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetic Gastroparesis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetic Gastroparesis Epidemiology (2016-2031)
5.3 Europe Diabetic Gastroparesis Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetic Gastroparesis Epidemiology (2016-2031)
5.5 Latin America Diabetic Gastroparesis Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetic Gastroparesis Epidemiology (2016-2031)
6 Diabetic Gastroparesis Treatment Market Overview
6.1 Diabetic Gastroparesis Treatment Market Historical Value (2016-2022)
6.2 Diabetic Gastroparesis Treatment Market Forecast Value (2023-2031)
7 Diabetic Gastroparesis Treatment Market Landscape
7.1 Diabetic Gastroparesis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Gastroparesis Treatment Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Diabetic Gastroparesis Treatment Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Diabetic Gastroparesis Treatment Market Segmentation
9.1 Diabetic Gastroparesis Treatment Market by Type
9.1.1 Market Overview
9.1.2 Surgical Treatment Products
9.1.3 Drugs
9.2 Diabetic Gastroparesis Treatment Market by Disease Indication
9.2.1 Market Overview
9.2.2 Compensated Gastroparesis
9.2.3 Gastric Failure
9.2.4 Others
9.3 Global Gastroparesis Treatment Market by End User
9.3.1 Market Overview
9.3.2 Hospitals
9.3.3 Specialty Clinics
9.3.4 Homecare
9.4 Global Gastroparesis Treatment Market by Route of Administration
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Injectables
9.5 Diabetic Gastroparesis Treatment Market by Region
9.5.1 Market Overview
9.5.2 North America
9.5.3 Europe
9.5.4 Asia Pacific
9.5.5 Latin America
9.5.6 Middle East and Africa
10 North America Diabetic Gastroparesis Treatment
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Diabetic Gastroparesis Treatment
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Diabetic Gastroparesis Treatment
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Diabetic Gastroparesis Treatment
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Diabetic Gastroparesis Treatment
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Evoke Pharma Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Allergen Pnc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Salix Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Theravance Biopharma Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Medtronics pLC
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Abbot
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Rhythm Pharmaceuticals
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Allergen plc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Astrazeneca plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Cadila Pharmaceuticals
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Neurogastrx Inc
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Bausch Health
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
22 Diabetic Gastroparesis Treatment - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket

Companies Mentioned

  • Merck KGaA
  • Compass Biomedical Inc.
  • STEMCELL Technologies Inc.
  • Sartorius AG
  • Life Science Group Ltd.



Table Information